Efficacy and Safety of 3 Doses of S201086/GLPG1972 Administered Orally Once Daily in Patients With Knee Osteoarthritis. A 52-week International, Multi-regional, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
Latest Information Update: 02 Jun 2026
At a glance
- Drugs Aldumastat (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Acronyms ROCCELLA
- Sponsors Galapagos NV; Lakefront Biotherapeutics
Most Recent Events
- 07 May 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
- 01 Nov 2024 Results published in the Osteoarthritis and Cartilage
- 01 Jul 2023 Results published in the Osteoarthritis and Cartilage